EVOLUTION
2020
- The Board of the Company approved the layout plan for the proposed injectable manufacturing unit at the Valthera facility.
- Received two ANDA approvals.
- Completed the first shipment of Mycophenolate Sodium Tablets to the US market.
2021
- Commenced operations at our second API facility in Limbasi.
- Underwent the third EU GMP inspection of our manufacturing facility in Dholka
2018
- Underwent the fifth USFDA inspection and received a ‘no action indicated’ classification for our Dholka facility.
- Granted GMP certification from the Food and Drugs Control Administration for our Valthera and Dholka units. Additionally, completed the second USFDA inspection at our Valthera facility and received the establishment inspection report.
- Established a joint venture in Japan to capitalize on growing business opportunities in the region.
2019
- Received two ANDA approvals.
- Expanded our company’s business in the critical care segment in India.
- Commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg.
2016
- Established a facility in Valthera, Gujarat.
- Gained recognition for our in-house R&D facility at Valthera from the Ministry of Science and Technology, Government of India.
- Secured investment from Helix.
2017
- Underwent the first USFDA inspection at our Valthera facility and received the establishment inspection report.
2014
- Received a certificate of drug substance registry for Ciclosporin JP from the Pharmaceuticals and Medical Devices Agency in Japan.
2015
- Underwent the fourth USFDA inspection of our Dholka facility, which concluded with a ‘closed’ status.
- Completed the second EU GMP inspection in May 2014.
- Received an accreditation certificate for foreign drug manufacturing for non-sterile drugs from the Minister of Health, Labour and Welfare of Japan.
2012
- Received the original drug substance registration certificate for Mycophenolate Mofetil from the Pharmaceuticals and Medical Devices Agency of Japan.
2013
- Underwent the third USFDA inspection, resulting in our API facility being classified as acceptable.
2010
- Received a drug master file registration certificate for Tacrolimus Hydrate from the Pharmaceuticals and Medical Devices Agency in Japan.
2011
- Underwent the first EU GMP inspection of our manufacturing facility conducted by the Government of Upper Bavaria- Central Medicines Control Bavaria (GMP/GCP).
- Launched CRAMs services specializing in new chemical entities (NCEs) and generic APIs.
2005
- Underwent our initial USFDA inspection, resulting in the classification of our API facility as acceptable.
2008
- Underwent the second USFDA inspection, resulting in our API facility being classified as acceptable.
2003
- Certification of our Dholka facility for commissioning and commencement of production of various enzymes by technical consultants.
2004
- Investment made by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in our company.
2001
- Our company has been renamed to More Reyra.
2002
- Increased production capacity of enzymes.